Pharmacia Corporation et al. v. Par Pharmaceutical, Inc.
judgment affirmed on appeal- Docket:
- 01-6011; 04-1478; 04-1496
- Court:
- U.S. District Court for the District of New Jersey; U.S. Court of Appeals for the Federal Circuit
- Filed:
- 2001-12-21
- Terminated:
- 2005-08-10
π Pharmacia Corporationπ Pharmacia ABπ Pharmacia Enterprises S.A.π Pharmacia & Upjohn Companyπ Columbia UniversityΔ Par Pharmaceutical, Inc.
ANDA litigation after Par's Paragraph IV notice concerning Xalatan/latanoprost. The District of New Jersey found the '368 patent unenforceable for inequitable conduct but upheld the '504 patent; the Federal Circuit affirmed. Narrative states the patents actually asserted were U.S. 5,422,368 and U.S. 5,296,504, not 6,030,999.